FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients...

April 15
Last Trade: 9.54 -0.26 -2.65

Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line,...Read more

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in...

April 15
Last Trade: 16.48 0.11 0.67

The North Star Ambulatory Assessment (NSAA) remained stable relative to declines reported in Becker natural history studies  Significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers associated with...Read more

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3%...

April 15
Last Trade: 94.41 0.89 0.95

APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1 IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide2; complement...Read more

UroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based...

April 15
Last Trade: 15.10 0.00 0.00

UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024 Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten the manufacturing process, simplify the reconstitution procedure, and potentially extend intellectual...Read more

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection...

April 15
Last Trade: 0.47 0.08 21.73

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval  PRINCETON, N.J., April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...Read more

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid...

April 15
Last Trade: 0.54 -0.09 -13.68

BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s...Read more

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...


Biggest Gainers

CompanyChangeLast Trade
UnitedHealth 6.32 1.44 $445.53
Third Harmonic Bio 4.59 63.75 $11.79
SIGA Technologies 3.44 63.24 $8.88
Integer 2.88 2.49 $118.65
Elevance Health 2.60 0.52 $500.09
United Therapeutics 2.49 1.07 $235.08
Humana 2.05 0.66 $314.64
Centene 1.99 2.81 $72.72
Cardinal Health 1.93 1.84 $107.03
Corbus Pharmaceuticals 1.87 4.58 $42.72
BioNTech 1.41 1.63 $87.89
Soleno Therapeutics 1.38 3.72 $38.52
Longeveron 1.24 73.37 $2.93
Amphastar Pharmaceuticals 1.16 2.93 $40.78
Immunovant 1.12 3.82 $30.47
Envoy Medical 1.02 20.20 $6.07
Avadel Pharmaceuticals 1.01 6.32 $17.00

Highest Volume

CompanyVolumeLast Trade
Soligenix 133,635,475 $0.47
Jaguar Health 113,572,916 $0.12
Longeveron 55,739,430 $2.93
Organovo 53,499,692 $1.35
Ginkgo Bioworks 43,910,238 $0.95
Marinus Pharmaceuticals 34,923,743 $1.30
Pfizer 28,620,603 $25.90
Sunshine Biopharma 14,900,471 $0.06
Teva Pharmaceutical 13,393,341 $13.23
IceCure Medical 12,188,326 $1.35
Geron 11,551,237 $3.45
Mobile-health Network Solutions 10,799,409 $16.65
Clover Health 10,189,571 $0.64
Bristol-Myers Squibb 9,957,202 $48.51
Walgreens Boots Alliance 9,937,347 $17.65
PacBio 8,901,784 $2.84
Gilead Sciences 7,709,301 $67.75
  • Upcoming FDA Catalysts

    • ImmunityBio (NASDAQ: IBRX) PDUFA Date

      April 23, 2024
    • Aquestive Therapeutics (NASDAQ: AQST) PDUFA Date

      April 28, 2024
    • Neurocrine Biosciences (NASDAQ: NBIX) PDUFA Date

      April 30, 2024
    • Day One Biopharmaceuticals (NASDAQ: DAWN) PDUFA Date

      April 30, 2024
    • X4 Pharmaceuticals (NASDAQ: XFOR) PDUFA Date

      April 30, 2024
    • Bristol-Myers Squibb (NYSE: BMY) PDUFA Date

      May 23, 2024

Featured Stock


Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....


Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...


Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...


Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...


Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: